Advances of second-line therapy for small-cell lung cancer
10.3760/cma.j.issn.1673-422X.2017.04.013
- VernacularTitle:小细胞肺癌二线治疗进展
- Author:
Hongjuan YANG
;
Conghua XIE
- Keywords:
Lung neoplasms;
Carcinoma;
small cell;
Retreatment;
Drug therapy
- From:
Journal of International Oncology
2017;44(4):290-293
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a highly malignant tumor, which is very sensitive to first-line chemotherapy, but easy to recurrence and metastasis early.So it always has poor prognosis.Second-line therapy for SCLC develops slowly.Topotecan is the only drug approved by US Food and Drug Administration as a second-line chemoradiotherapy.Numerous studies on molecular targeted therapy and immunotherapy are being carried out, but most of them have no or little benefit.Rovalpituzumab tesirine (Rova-T) targeted antibody-drug conjugate (ADC) which is published at the 2016 American Society of Clinical Oncology Annual Meeting shows a good anti-tumor activity, which seems to bring a new dawn of molecular targeted therapy.
